Prime Medicine (PRME) Other financing activities (2022 - 2026)

Prime Medicine (PRME) has 5 years of Other financing activities data on file, last reported at $393000.0 in Q1 2026.

• Quarterly Other financing activities changed N/A year-over-year to $393000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 93.33% YoY) and the FY2025 annual result came in at $781000.0, down 95.85% from the prior year.
• Other financing activities eased to $393000.0 in Q1 2026, from $781000.0 in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $17.6 million in Q2 2024 to a low of -$68000.0 in Q2 2023.
• A 5-year average of $2.1 million and a median of $293500.0 in 2023 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2023 — Other financing activities gained 24.36% — and 2024, when it jumped 25982.35%.
• Tracing PRME's Other financing activities over 5 years: stood at $156000.0 in 2022, then advanced by 24.36% to $194000.0 in 2023, then jumped by 8972.16% to $17.6 million in 2024, then slumped by 95.56% to $781000.0 in 2025, then slumped by 49.68% to $393000.0 in 2026.
• The last three Other financing activities figures came in at $393000.0 (Q1 2026), $781000.0 (Q4 2025), and $17.6 million (Q2 2024), per Business Quant data.